Monitoring of tumor cells by flow cytometry permits rapid evaluation of disease progression in monomorphic epitheliotrop...
...Published in Cytometry. Part B, Clinical cytometry
Best practices for optimization and validation of flow cytometry-based receptor occupancy assays.
...Published in Cytometry. Part B, Clinical cytometry
In the development of therapeutic compounds that bind cell surface molecules, it is critical to demonstrate the extent to which the drug engages its target. For cell-associated targets, flow cytometry is well-suited to monitor drug-to-target engagement through receptor occupancy assays (ROA). The technology allows for the identification of specific...
Normal or reactive minor cell populations in bone marrow and peripheral blood mimic minimal residual leukemia by flow cy...
Published in Cytometry. Part B, Clinical cytometry
Measurable residual disease (MRD) is a strong independent poor prognostic factor for acute leukemia. Multiparameter flow cytometry (FCM) is a commonly used MRD detection method. However, FCM MRD detection is not well standardized, and the interpretation is subjective. There are normal/reactive minor cell populations in bone marrow (BM) and peripher...
Flow cytometric basophil activation tests: Staining of exteriorized basophil granule matrix by fluorescent avidin versus...
...Published in Cytometry. Part B, Clinical cytometry
Staining of exteriorized basophil granule matrix by fluorescent avidin might be a reliable technique to monitor basophil degranulation. This study compares the avidin-based technique with the upregulation of CD203c and appearance of CD63 in response to various stimuli. Fourteen individuals responsive to anti-IgE, nine healthy controls, and five bir...
Bone marrow infiltration by flow cytometry at diffuse large B-cell lymphoma NOS diagnosis implies worse prognosis withou...
...Published in Cytometry. Part B, Clinical cytometry
The significance of discrepant findings between histology (BMB) and flow cytometry (FC) in bone marrow (BM) examination at diffuse large B-cell lymphoma (DLBCL) diagnosis is uncertain. We performed a 5-year retrospective single-center study of patients diagnosed by DLBCL not otherwise specified (n = 82), divided into three groups according to BM in...
Clinical and laboratory features associated with myeloperoxidase expression in pediatric B-lymphoblastic leukemia.
Published in Cytometry. Part B, Clinical cytometry
B-lymphoblastic leukemia (B-ALL) is the most common childhood malignancy, and its diagnosis requires immunophenotypically demonstrating blast B cell lineage differentiation. Expression of myeloperoxidase (MPO) in B-ALL is well-described and it has been recognized that a diagnosis of mixed phenotype acute leukemia should be made cautiously if MPO ex...
CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab.
Published in Cytometry. Part B, Clinical cytometry
Daratumumab is an anti-CD38 immunotherapeutic drug that has increasingly been used to treat patients with heavily pre-treated and relapsed/refractory multiple myeloma. In so doing, the detection of CD38 antigen on plasma cells by flow cytometry is impeded. We hypothesized that alternative markers can be used in place or in addition to CD38 when det...
Characteristic flow cytometric profile of ectopic intra-thyroidal thymic tissue in children.
Published in Cytometry. Part B, Clinical cytometry
14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual...
Published in Cytometry. Part B, Clinical cytometry
The diagnosis of CLL/SLL relies on flow cytometric immunophenotyping. Increasing emphasis is being placed on precise detection of the minimal residual disease. Following antigen recommendations of ERIC and ESCCA's Harmonization Project, we validated a 14-color assay for the characterization CD5+ lymphoproliferative neoplasms and CLL MRD with a sens...
Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for meas...
...Published in Cytometry. Part B, Clinical cytometry
Accurate knowledge of expression patterns/levels of commonly used MRD markers in regenerative normal-B-cell-precursors (BCP) is highly desirable to distinguish leukemic-blasts from regenerative-BCP for multicolor flow cytometry (MFC)-based measurable residual disease (MRD) assessment in B-lymphoblastic leukemia (B-ALL). However, the data highlighti...
